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ABSTRACT 
 
Grinding-induced particle size reduction to submicron order is an effective way 
to enhance the dissolution rate.  For effective size reduction of drug particles, water-
soluble polymers and surfactants have been used as additives to inhibit particle 
agglomeration and improve the physicochemical properties of the drug.  The purpose of 
this study was to investigate the stability and the formation mechanism of drug 
nanoparticles obtained from a ternary system consisting of a poorly water-soluble drug, 
polyvinylpyrrolidone (PVP), and sodium dodecyl sulfate (SDS).  Interactions among drug 
and additive components should provide essential information for the mechanism of drug 
nanoparticle formation. 
Seventeen poorly water-soluble drugs were employed in this study.  Various 
molecular weights of PVP, PVP K12 (Mw ∼2,500); PVP K17 (Mw ∼10,000); PVP K30 (Mw 
∼50,000); PVP K90 (Mw ∼1,000,000), and SDS were used as pharmaceutical additives in 
this study.  Cellulose derivatives, such as hydroxypropylmethylcellulose (HPMC); 
hydroxypropylcellulose (HPC) and methylcellulose (MC), and sodium deoxycholate were 
also used to investigate the effect of ternary composition on the grinding-induced 
nanoparticle formation.  The drug, PVP and SDS were mixed at a weight ratio of 1:3:1 and 
ground for 30 min by means of vibrational rod mill.  The physical state and solid state 
interactions were evaluated using powder X-ray diffraction (PXRD), solid-state 13C NMR 
spectroscopy and high resolution scanning electron microscopy (SEM).  The nanoparticles 
obtained from the suspension of ground mixture were investigated by dynamic light 
scattering, HPLC quantitation, environmental SEM and zeta potential measurements.   
Ternary ground mixtures (GMs) of drug/PVP K17/SDS were prepared with 
seventeen poorly water-soluble drugs.  Most of the poorly water-soluble drugs used in this 
study produced the nanoparticle formation after dispersing the ternary GMs into distilled 
water.  Stability and mechanism of drug nanoparticle formation were investigated by 
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focusing on phenytoin, probucol and griseofulvin.  The drug nanoparticle formation was 
also observed when the ternary GMs were dispersed into the dissolution media.  The mean 
particle size of the dispersed particles was still less than 250 nm after storage at 25°C for 1 
month, indicating the long-term stability of drug nanoparticles.  Quantitative 
determination of drug content demonstrated that more than 93% of drug was recovered as 
nanoparticles, smaller than 0.8 µm from the ternary GMs, whereas the nanoparticles were 
hardly gained from binary GMs composed of drug and PVP K17 or drug and SDS.  HPLC 
chromatograms of the drugs in the suspensions after 28 days of storage did not show any 
difference from those of the intact suspension, indicating that drugs were stable in the 
suspensions.  Powder X-ray diffraction analysis for the dispersed particles accumulated by 
ultracentrifugation indicated that the dispersed particles existed as nanocrystals.  The zeta 
potential measurement revealed that the obtained nanoparticles were stable in aqueous 
media because the particle agglomeration was effectively inhibited by the adsorption of 
both PVP and SDS onto the particle surface. 
Effects of PVP molecular weight on the solid-state intermolecular interactions 
among probucol/PVP/SDS ternary GM and the issued nanoparticle formation were 
investigated by solid-state NMR spectroscopy.  Particle size analysis demonstrated that 
probucol nanoparticles were obtained effectively when the low molecular weight PVP was 
used.  The PXRD results indicated that drug amorphization during grinding was 
accelerated with the decrease in PVP molecular weight.  Intermolecular interactions 
among components of the ternary GMs were characterized by solid-state cross 
polarization and magic angle spinning (CP/MAS) 13C-NMR spectroscopy.  The solid-state 
13C CP/MAS NMR results indicated that the lower molecular weight PVP interacted with 
probucol and SDS more strongly than the higher molecular weight PVP in the ternary GM.  
This finding was consistent with the result that smaller drug nanoparticles were obtained 
using the lower molecular weight PVP.  SEM images of probucol/PVP K12/SDS 
confirmed the presence of nanoparticles (15-25 nm) in the GM.  Probucol interacted with 
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PVP through hydrogen bonding but not with SDS.  Grinding-induced solid-state 
interactions of probucol-PVP and PVP-SDS were expected to contribute to the production 
and stabilization of drug nanoparticles, and were able to be detected using solid state 13C 
NMR.  The interactions in both probucol-PVP and also PVP-SDS should occur 
simultaneously to generate nanometer-sized particles of probucol.   
Possible mechanism for drug nanoparticle formation was speculated as follows:  
after the GM was dispersed into aqueous media, nano-crystalline drug particles were 
produced and the agglomeration was effectively inhibited due to the adsorption of PVP 
and SDS onto the particle surface.  Complex formation between PVP and SDS would also 
be an important factor for the nanoparticle formation, as the latter was not possible in the 
binary GMs.  Consequently, the particle size of drugs in the suspension remained constant 
for long time due to the inhibitory effect of adsorption by both PVP and SDS. 
Finally, drug nanoparticle formation from a ternary ground mixture consisting of 
a poorly water-soluble drug, HPMC and SDS was investigated.  Flurbiprofen, which did 
not show nanoparticle formation by co-grinding with PVP and SDS, was used as a model 
drug.   Flurbiprofen, HPMC and SDS were mixed at the weight ratio of 1:3:1 and ground 
for 30 min by vibrational rod mill.  The drug nanoparticle formation was observed after 
the ternary GM was dispersed into distilled water.  Molecular interactions both between 
flurbiprofen and HPMC then polymer and surfactant were found to be important factors 
for the nanoparticle formation.  The GM was stable for 2 months at the storage condition 
of 40ºC and  RH 22%.  Mean particle size of the dispersed particles was still less than 350 
nm after storage at 25°C for 1 month.  It was found that the drug/HPMC/SDS ternary 
grinding method was applicable not only for flurbiprofen but also for other hydrophobic 
drugs, such as tolbutamide, probucol, phenytoin and griseofulvin.  The drug nanoparticles 
were also obtained using other cellulose derivatives and bile salt, indicating that these 
pharmaceutical excipients were alternative to PVP and SDS for the grinding-induced drug 
nanoparticle formation. 
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In conclusion, drug/PVP/SDS ternary grinding method was successfully applied 
for the preparation of nanoparticles of hydrophobic drugs.  Co-existence of both PVP and 
SDS during the grinding process with drug crystals, was required for the effective particle 
size reduction since, the binary systems of drug/PVP and drug/SDS showed no 
nanoparticle formation.  The nanosuspension prepared from the GM was stable at least for 
1 month, indicating the long-term stability of drug nanoparticles.  It was suggested that 
grinding-induced solid-state interactions both between drug and PVP then PVP and SDS 
contributed to the nanometer-sized particle production and stabilization.  Smaller 
nanoparticles were obtained by using low molecular weight PVP.  After dispersing the GM 
into aqueous media, nano-crystalline drug particles were produced and the agglomeration 
of nanoparticles was inhibited due to the adsorption of PVP and SDS onto the particle 
surface.  Since other polymers and surfactants such as cellulose derivatives and bile salts 
were also applied to prepare drug nanoparticles instead of PVP and SDS, drug/water-
soluble polymer/surfactant ternary grinding could be a promising method to prepare drug 
nanoparticles for the purpose of bioavailability enhancement of poorly water-soluble drugs. 
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INTRODUCTION 
 
Solubility enhancement of poorly water-soluble drugs is a crucial issue to 
improve solubility and bioavailability 1-3).  Numerous attempts to improve the dissolution 
behavior have been made by using solid dispersions of drugs with polymers 4-9), semi-
solid dispersions with surfactants 10) and inclusion complexes with cyclodextrins 11, 12).  
Particle size reduction of drug is also an effective way to increase both solubility and 
dissolution rate 13-15).  For the particle size reduction, a mechanochemical method such as 
co-grinding of a drug with additives is a promising way to obtain the dispersed system 16-
23).  The mechanical stress brings about distortion of particles, amorphization, polymorphic 
transformation and molecular interaction between drug and carrier 24-32).  Several studies 
have revealed the grinding-induced particle size reduction and the enhanced dissolution 
rate 16-23, 28). 
Conventional grinding, commonly results in particles much greater than 1 µm 
due to aggregation 24, 33).  Recently, wet co-grinding technique has been developed to 
enable the preparation of grinding–induced drug nanoparticles 34-41).  Liversidge et al. 
proposed the preparation method for crystalline nanoparticle by wet co-grinding of 
danazol with polyvinylpyrrolidone 34).  Oral absorption of poorly-water soluble drugs in 
nanocrystal form was remarkably improved 34-41).  However, the wet process can not be 
applied to drugs that are easily degraded by hydrolysis.  Storage condition of the sample at 
liquid state is also not favorable.  Compared with the latter, dry co-grinding process has 
some advantages for solid pharmaceuticals due to the simple preparation process with 
organic solvent free.  It is well known that the wet co-grinding method is effective to 
produce stable nanosuspension 34-42); however, preparation of the stable nanosuspension by 
the dry co-grinding process has been rarely reported.    
For the effective size reduction of the drug particles, water-soluble polymers and 
surfactants have been used as additives to inhibit the particles agglomeration and improve 
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the physicochemical properties of the drug 4).  Polyvinylpyrrolidone (PVP) is a commonly 
used water-soluble polymer in a variety of pharmaceutical formulations due to its low 
toxicity and chemical stability 43).  Improved stability and dissolution properties of 
hydrophobic drugs prepared with PVP have been demonstrated for several kinds of drugs 
44-54).  Sodium dodecyl sulphate (SDS) has been used as an emulsifying agent in 
pharmaceutical formulations 55).  Because of intrinsic toxicity problems, SDS is often used 
in combination with other excipients to obtain enhanced solubility and dispersion stability 
of drug particles 56-60).   
Specific interactions among components of the ternary system should offer a 
necessary understanding of the mechanism of nanoparticle formation 61).  Alden et al. 
reported that interactions among ternary components of griseofulvin, polyethylene glycol 
and SDS resulted in solid molecular dispersion and enhancement of dissolution rate 57).  
The formation of hydrogen bonding between furosemide or indomethacin and PVP could 
induce amorphous molecular dispersion and inhibit drug crystallization 44, 47).  
Polyvinylpyrrolidone of different molecular weights would have different effects on drug-
PVP interactions.  It was found that low molecular weight PVP was more effective in the 
decrease of ibuprofen and piroxicam crystallinity due to a greater interaction 49, 62).  
Interactions between PVP and SDS are of high interest for the explanation of their ability 
to stabilize the system.  There are many studies, which have demonstrated the PVP-SDS 
interactions in aqueous solutions 63-76).  However, detailed information of the PVP-SDS 
interactions in the solid state is not readily available. 
Several techniques such as solid-state 13C-NMR, PXRD and infared (IR) 
spectroscopy have been extensively utilized to characterize the nature of the interactions 
between drugs and additives 77, 78).  Powder X-ray diffraction (PXRD) measurement and 
IR spectroscopy are commonly used methodologies to investigate solid-state properties of 
drugs and additives 49-54).  Powder X-ray diffraction has been applied to investigate 
crystalline states of ternary GM 79, 80).  It has also given complemental information about 
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molecular states of drugs and excipients with solid-state NMR spectroscopy 81).   IR 
spectroscopy was effectively applied to investigate the interaction between drug and PVP 
58, 59).  However, IR spectroscopy is not sensitive to weak interactions between 
components. 
Solid-state 13C NMR spectroscopy is a powerful method for the study of 
pharmaceutical materials in solid state.  The combined techniques of cross polarization 
(CP) and magic angle spinning (MAS) give high-resolution 13C spectra, and molecular 
level information.  The application of solid-state NMR spectrometry to the 
characterization of solids is particularly attractive due to the sensitivity of the chemical 
shift to molecular conformation, and the chemical environment in the crystal structure 82, 
83).  Solid-state 13C spectroscopy has been used for the analysis of the amorphous content, 
polymorphs, mixed crystals and mixtures of drugs in the presence of excipients 84-88).  
Moreover, this technique also can be used for investigation of intermolecular interactions 
in the formulation of pharmaceutical agents in polymer matrices.  The interactions 
influence the changes in the local electron density which leads to some chemical shifts of 
drug and additives 89-92). 
Drug-PVP and drug-SDS binary grinding may be applicable for particle size 
reduction of drugs, though the obtained particles easily agglomerate after storage of the 
suspension.  The combined use of a polymer and a surfactant contributes to the effective 
stabilization of the ternary system by adsorption of a polymer-surfactant complex on the 
particle surface 93-103).  The ternary system of a poorly-water soluble drug with polymer 
and surfactant should be a potential candidate to benefit the drug nanoparticle formation 
and stabilization. 
Recently, Itoh et al. reported that ternary ground mixtures of N-5159 with PVP 
and SDS showed colloidal nanoparticle formation in distilled water 104).  Since small 
particles are usually highly energetic and tend to increase in size, it is important to 
evaluate the stability of prepared nanoparticles for practical use 78).  The mechanism of 
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nanoparticles formation from the ternary co-ground mixture is another significant point for 
the application of this preparation procedure to other hydrophobic drugs. 
The purpose of this study is to investigate physicochemical properties and the 
mechanism of drug nanoparticle formation, obtained from a poorly water-soluble drug, 
polyvinylpyrrolidone (PVP), and sodium dodecyl sulfate (SDS) ternary ground mixture 
(GM).  Results and discussion of this thesis are exposed in four Chapters.   In Chapter I, 
investigations were carried out on the preparation of drug nanoparticles from drug/PVP 
K17/SDS ternary GMs using seventeen poorly water-soluble drugs and physicochemical 
and long–term stability.  On the later experiments, phenytoin, probucol and griseofulvin 
were used as model drugs.  Stabilization of drug nanoparticles obtained in JP first and 
second fluids was also evaluated.  Physicochemical properties of the ternary GMs were 
determined by powder X-ray diffraction and particle size distribution measurements.  In 
order to estimate the mechanism of nanoparticle formation, the role of PVP and SDS in 
the crystallization of poorly water-soluble drugs was discussed in terms of the amount of 
nanoparticle formation and the change in magnitude of zeta potential. 
Further investigations to find out how the nanoparticles were made in the 
suspension, would be an attractive research to get more insight into a possible mechanism 
of nanoparticle formation.  It is of high interest to investigate the effect of PVP molecular 
weight on drug-additive interactions at the molecular level.  In Chapter II, the effect of the 
molecular weight of PVP on drug nanoparticle formation obtained from 
probucol/PVP/SDS ternary ground mixture was investigated.  Probucol, which is one of 
the cholesterol-lowering agents used in the treatment of hypercholesterolemia, was used as 
a model drug.  Probucol has two crystalline forms and is practically insoluble in water 
(5ng/ml at 25°C) 46, 105).  Interactions among drug and/or additive components should 
provide crucial information for the role of PVP and SDS as stabilizers in drug nanoparticle 
formulation.  The physical and solid states interactions among probucol, PVP and SDS 
were evaluated using powder X-ray diffraction and solid state 13C NMR.  In chapter III, 
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the proposed mechanism of nanoparticle formation was demonstrated. 
To apply the grinding-induced drug nanoparticle formation to other hydrophobic 
drugs, different kinds of combinations of the drug/polymer/surfactant system should be 
investigated instead of the drug/PVP/SDS ternary system.  In Chapter IV, the 
drug/hydroxypropylmethylcellulose (HPMC)/SDS ternary system was used to investigate 
the grinding-induced drug nanoparticle formation.  Flurbiprofen, which did not show 
nanoparticle formation, by co-grinding with PVP and SDS, was used as a model drug to 
prepare the nanoparticle by co-grinding.  The effect of ternary components on the drug 
nanoparticle formation was investigated by using cellulose derivatives such as 
methylcellulose (MC) and hydroxypropylcellulose (HPC), and a bile salt which is sodium 
deoxycholate (NaDC). 
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EXPERIMENTAL 
 
CHAPTER I 
Formation and stability of drug nanoparticles obtained from 
drug/PVP/SDS ternary ground mixtures 
 
Materials 
 Phenytoin and probucol were obtained from Dainippon Pharmaceutical Co., Ltd. 
(Japan) and Daiichi Pharmaceutical Co., Ltd. (Japan), respectively.  Griseofulvin, 
carbamazepine, furosemide, flufenamic acid, glibenclamide, indomethacin, mefenamic 
acid, piroxicam and tolbutamide were purchased from Wako Pure Chemical Industries, 
Ltd. (Japan).  Flurbiprofen was supplied by Kaken Pharmaceutical Co., Ltd, (Japan). 
Albendazole, nifedipine, nitrazepam, phenylbutazone and reserpine were purchased from 
Sigma Chemical Co. (Germany), Moeh S.A. (Spain), Sankyo Co., Ltd. (Japan), Lancaster 
Synthesis (England) and Tokyo Kasei Kogyo Co., Ltd. (Japan), respectively.   
Polyvinylpyrrolidone (PVP), PVP K 17, was obtained from ISP Technologies, Inc. 
(U.S.A.). Sodium dodecyl sulphate (SDS) was purchased from Wako Pure Chemical 
Industries Ltd. (Japan). All chemicals were of reagent grade and used as received. 
  
Preparation of physical mixtures (PMs) 
 Drug (0.250 g) and the ground mixture of PVP K17/SDS at a weight ratio of 3:1 
(1.000 g) were physically mixed in a glass vial by using a vortex mixer. 
 
Preparation of ground mixtures (GMs) 
 For the ternary system, the drug (0.500 g), PVP K17 (1.500 g) and SDS (0.500 
g) (weight ratio of 1:3:1) were mixed and then ground at room temperature by a 
vibrational rod mill (CMT TI-200, Japan) for 30 min.  The grinding cell was made of 
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aluminium oxide.  For the binary system, the drug (0.625 g) and PVP K17 (1.880 g) or the 
drug (1.250 g) and SDS (1.250 g) were ground by the same method as described above. 
 
Preparation of the suspensions from the ground mixtures 
 The GM was dispersed into distilled water and then sonicated for 2 min to make 
the suspension.  The drug concentration in the suspension was 0.50 mg/ml.  The Japanese 
Pharmacopoeia (JP 14) first fluid (pH 1.2) and second fluid (pH 6.8) were also used as 
liquid media instead of distilled water.  In case of using JP second fluid, total amount of 
the sample was half sized (the concentration of drug was 0.25 mg/ml) due to the 
incompatibility between SDS and potassium ion in the solution. 
 
Powder X-ray diffraction (PXRD) measurement 
 The powder X-ray diffraction (PXRD) measurements of samples were 
conducted on a Rigaku (model Miniflex) powder X-ray diffractometer (Tokyo, Japan).  
The measurement conditions were as follows: a Cu target, a Ni filter, a voltage of 30 kV, a 
current of 15 mA, a scanning angle of 2 to 35° and a scanning speed of 4°/min. 
 
Particle size analysis 
 The volumetric particle size distribution for each suspension was determined by 
a dynamic light scattering method using Microtrac UPA® (Nikkiso, Japan).  The UPA 
possesses a detection range of 0.003-6 µm.  The particle size distribution was measured 
after sonication and after sonication and after storage at room temperature for 4 h. 
 
Determination of zeta potential 
 A zeta potential for each suspension in distilled water was determined using 
ZetaPALS® (Nikkiso, Japan).  The average of five tests was reported. 
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Quantitative determination of the drug as nanoparticles 
 Each sample [PMs, binary GMs (drug/PVP K17, 1:3 w/w and drug/SDS, 1:1 
w/w) and ternary GM] containing 5 mg of drug was dispersed in 10 ml of distilled water 
then, sonicated for 2 min.  The suspensions were stored at 25°C for 4 h then, filtered 
through a 0.8 µm membrane filter (nitrocellulose filter, Millipore®).  The filtrates obtained 
were appropriately diluted with the HPLC mobile phase solution. The drug concentration 
in nanoparticle fractions was determined by using HPLC (LC-6A, Shimadzu Co., Japan).  
The mobile phase was delivered at a flow rate of 1.0 ml/min through a C-18 Capcell Pak® 
(4.6 mm I.D.×15 cm) at 40 °C and the detection wavelength was 254 nm.  The mobile 
phase for phenytoin and griseofulvin was acetonitrile/distilled water/phosphoric acid 
80/120/1 (v/v/v) and that for probucol was acetonitrile/distilled water 185/15 (v/v). 
 
Crystalline state characterization of nanoparticles 
 The suspension was ultracentrifuged (Himac CP 90α, Hitachi, Japan) at 40,000 
rpm (approx. 100,000 × g) for 30 min.  The nanoparticle sediment was re-suspended in 
distilled water for washing, then ultracentrifuged again.  After discarding the supernatant 
solution, the sediment was dried in a vacuum desiccator.  The PXRD measurement was 
performed to investigate the crystalline state. 
 
Stability study 
 Solid-state stability studies of the GM powder were performed by storage of 
samples in a desiccator containing a saturated aqueous solution of potassium acetate, 
which results to a relative humidity (RH) of 22 percent at 40°C.   
 Stability studies of the GM suspensions were investigated.  Particle size analysis 
and quantitative determination of the drug as nanoparticles were performed after storage at 
25°C for 0 and 4 h, then 1, 3, 7, 14 and 28 days. 
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CHAPTERS II & III 
Molecular interaction among components of the probucol/PVP/SDS  
ternary system investigated by solid-state NMR, & Speculation on  
the mechanism of grinding-induced nanoparticle formation 
 
 
Materials 
 Probucol was supplied by Daiichi Pharmaceutical Co., Ltd. (Japan). 
Polyvinylpyrrolidone, PVP K12 (Kollidon® 12 PF, Mw ∼2,500) was obtained from BASF 
Japan Ltd. and PVP K17 (Plasdone® C15, Mw ∼10,000), PVP K30 (Plasdone® K29/32, Mw 
∼50,000) and PVP K90 ((Plasdone® K90, Mw ∼1,000,000) were obtained from ISP 
Technologies, Inc. (USA).  Sodium dodecyl sulphate (SDS) was purchased from Wako 
Pure Chemical Industries Ltd. (Japan).  All other chemicals used were of reagent grade 
and used as recieved. 
 
Preparation of ground mixtures (GMs) 
 Probucol (0.500 g), PVP (1.500 g) and SDS (0.500 g) (weight ratio of 1:3:1) 
were physically mixed in a glass vial using a vortex mixer (physical mixture, PM).  For 
the preparation of ternary ground mixtures, the PM was ground in a vibrational rod mill 
(TI-200, Heiko Seisakusho, Japan) for definite intervals.  The grinding cell was made of 
aluminium oxide.  For the binary system, probucol (0.625 g) and PVP (1.875 g) or 
probucol (1.250 g) and SDS (1.250 g) were ground by the same method as described 
above. 
 
Powder X-ray diffraction (PXRD) measurement 
 The Powder X-ray diffraction (PXRD) measurement was performed on a Rigaku 
Miniflex diffractometer (Tokyo, Japan).  Measurements were performed at a voltage of 30 
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kV, a current of 15 mA, a scanning speed of 4° min-1, and a CuKα radiation source. 
 
Particle size analysis 
 The GM was dispersed into distilled water and then sonicated for 2 min to make 
the suspension.  Drug concentration in the suspension was 0.50 mg/ml.  The volumetric 
particle size distribution for each suspension was determined by a dynamic light scattering 
method using Microtrac UPA® (Nikkiso, Japan; measurement range: 0.003-6 µm) and by 
the light scattering method using Microtrac FRA® (Nikkiso, Japan; measurement range: 
0.1-700 µm).   
 
Solid-state nuclear magnetic resonance (NMR) spectroscopy 
 13C-NMR spectra were measured on a JNM-LA400 NMR spectrometer (JEOL, 
Japan) operating at 100.4 MHz with a CP/MAS (cross-polarization/magic angle spinning) 
probe. The sample (ca. 200 mg) was contained in a cylindrical rotor made of ceramic 
materials, and spun at 5000 Hz.  The contact time and the repetition time were fixed at 5 
ms and 5 s, respectively.  The spectral width and number of data points were 40 kHz and 
16384 respectively.  To achieve an appropriate signal-to-noise ratio, the number of 
accumulations was 10000 for ternary systems and 2260 for intact and binary systems.  
Experimental conditions were as follows: temperature at 25.0ºC, a 1H decoupling field 
amplitude of 50 kHz, and a rf field amplitude for cross polarization of 50 kHz.  The wave 
separation of 13C-NMR spectra were estimated with computer-fitted curves using ALICE2 
software (JEOL, Japan). 
 
High resolution scanning electron microscopy (SEM) analysis 
 Scanning electron microscopy was performed using a Nova 200 NanoLab (FEI 
Company, Japan) operated at 3 kV.  A sample was fixed to a SEM stage using a carbon 
paste then coated with a platinum sputter. 
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Preparation of freeze-dried PVP K90/SDS 3:1  
 PVP K90 (3.00 g) and SDS (1.00 g) were dissolved in 8.00 ml of distilled water.  
The sample was frozen at -180°C in a liquid nitrogen.  Then, the sample was freeze-dried 
under 8 Pa, a trap temperature of -45°C for 48 h, using EYELA freeze dryer FD-1000 
(Tokyo Rikakikai Co., Ltd., Japan).  
 
Environmental SEM analysis 
 The nanoparticles in the suspension of probucol/PVP K17/SDS 1:3:1 GM were 
observed using Quanta FEG (FEI company) environmental scanning electron microscope.  
The chamber was held constant at 3°C, 4.5 Torr with an accelerating voltage of 20 kV.     
 
Stability study 
 Stability studies of the GM suspensions were investigated by particle size 
analysis after the storage at 25°C for 0 and 4 h, then 1, 3, 7, 14, 21 and 28 days. 
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CHAPTER IV 
Drug nanoparticle formation from  
drug/HPMC/SDS ternary ground mixtures 
 
Materials 
 Flurbiprofen and probucol were supplied by Kaken Pharmaceutical Co., Ltd. 
(Japan) and Daiichi Pharmaceutical Co., Ltd. (Japan), respectively.  Tolbutamide, 
phenytoin and griseofulvin were purchased from Wako Pure Chemical Industries, Ltd. 
(Japan).  Polyvinylpyrrolidone K17 (PVP) was obtained from ISP Technologies, Inc. 
(U.S.A.).  Hydroxypropylmethylcellulose 2910 (HPMC, HPMC 2910 TC5EW®) and 
Methylcellulose (MC, MC-SM4®) were supplied by Shin-Etsu Chemical Co., Ltd. (Japan).  
Hydroxypropyl cellulose (HPC, Nisso HPC-SSL®) was obtained from Nippon Soda Co., 
Ltd. (Japan).  Sodium dodecyl sulphate (SDS) was purchased from Wako Pure Chemical 
Industries Ltd. (Japan).  All chemicals were of reagent grade and used as received. 
 
Preparation of physical mixtures (PMs) 
 Drug (250 mg) and 1.00 g of a ground mixture of HPMC/SDS (HPMC/SDS = 
3/1 w/w) were physically mixed in a glass vial by using a vortex mixer.    
 
Preparation of ground mixtures (GMs)  
 Drug (0.500 g), HPMC (1.500 g) and SDS (0.500 g) were mixed and then 
ground at room temperature by a vibrational rod mill (CMT TI-200, Japan) for 30 min.   
For the binary system, drug (0.625 g) and HPMC (1.880 g) or drug (1.250 g) and SDS 
(1.250 g) were ground by the same method as described above.  The GM suspension was 
obtained by dispersing the GM into distilled water.    
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Powder X-ray diffraction (PXRD) measurement  
 Powder X-ray diffraction (PXRD) measurements were performed on a Rigaku 
Miniflex powder X-ray diffractometer (Rigaku, Japan) under the following conditions: a 
Cu target, a Ni filter, a voltage of 30 kV, a current of 15 mA, a scanning angle of 2 to 35° 
and a scanning speed of 4°/min. 
 
Fourier transform infrared (IR) spectroscopy 
 Fourier transform infrared spectroscopy was carried out by the KBr disk method.   
IR spectra of the samples were measured on a JASCO 230 FT-IR spectrometer (JASCO 
Corporation, Japan). 
 
Particle size analysis 
 The GM was dispersed into distilled water and then sonicated for 2 min to make 
the suspension.  Drug concentration in the suspension was 0.50 mg/ml.  The volumetric 
particle size distribution for each suspension was determined by a dynamic light scattering 
method using Microtrac UPA® (Nikkiso, Japan; measurement range: 0.003-6 µm) and by 
the light scattering method using Microtrac FRA® (Nikkiso, Japan; measurement range: 
0.1-700 µm).  The particle size distribution was measured after sonication and after 
sonication and after storage at room temperature for 4 h.  
 
Stability study 
 Solid-state stability studies of the GM powder were performed by storage of 
samples in a desiccator containing a saturated aqueous solution of potassium acetate, 
which results to a relative humidity (RH) of 22 percent at 40°C.   
 Stability studies of the GM suspensions were investigated by particle size 
analysis after storage at 25°C for 7, 14, 21 and 28 days. 
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RESULTS AND DISCUSSION 
CHAPTER I  
Formation and stability of drug nanoparticles  
obtained from drug/PVP/SDS ternary ground mixtures 
 
1. Nanoparticle formation from ternary ground mixtures  
 Itoh et al. reported that N-5159/PVP K17/SDS ternary ground mixture formed 
N-5159 nanoparticles when the ternary GM was dispersed into the distilled water.  They 
also proposed the suitable mixing ratio for drug/PVP/SDS at a weight ratio of 1:3:1 as it 
showed the highest recovery of drug nanoparticles 104).  To investigate the applicability of 
this procedure for active pharmaceutical ingredients, it is necessary to examine the 
nanoparticle formation of ternary ground mixtures by using other poorly water-soluble 
drugs.  In this study, seventeen poorly water-soluble drugs were used to investigate the 
drug nanoparticle formation induced by grinding. The chemical structures and 
physicochemical properties of drugs and pharmaceutical excipients used in this study are 
presented in Table 1-1 and Fig. 1-1, respectively.  Appearance of the suspensions obtained 
from ternary PMs and GMs was quite different (Fig. 1-2).  Physical mixtures could not be 
dispersed in distilled water at the beginning, then continuous sonication made the 
suspension turbid as the wettability of the hydrophobic drug was slightly improved by the 
presence of hydrophilic additives.  On the contrary, the ternary GMs were easily dispersed 
in to distilled water due to their good wettability, and the suspension became turbid 
immediately.  For example, the suspension obtained from the ternary GM of probucol 
exhibited pearl blue color.  After storage for 4 h, both the change in color of the 
suspensions, and the precipitation of the drug were not observed. 
 The mean volumetric particle size of each suspension obtained from drug/PVP 
K17/SDS ternary GM dispersing into water is shown in Table 1-2.  The GMs of all drugs, 
except flurbiprofen, provided the suspension with the particle size in the submicron region. 
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Table 1-1   Chemical structures and physicochemical properties of drugs used in this study 
  
Drug Chemical structure Molecular weight 
Melting 
point 
(°C) 
Water 
solubility 
1.  Probucol 
C31H48O2S2
      
516.84 125-126 5 ng/ml at  25 °C 46)  
2.  Piroxicam 
C15H13N3O4S 
 
331.35 198-200 23 µg/ml at 22°C 106)
3.  Reserpine 
C33H40N2O9 
608.68 260-262 < 0.1 mg/ml at 22°C 106)
4.  Phenytoin 
C15H12N2O2
 
252.27 294 32 µg/ml at 22°C 107)
5.  Griseofulvin 
C17H17ClO6
352.77 220 64 µg/ml at 25°C 108)
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 Drug Chemical structure Molecular weight 
Melting 
point (°C) 
Water 
solubility 
6.  Nifedipine 
C17H18N2O6
 
346.33 172-174 56 µg/ml at 37°C 20)
7.  Furosemide 
C12H11ClN2O5S 
330.74 295 73 µg/ml at 30°C 106)
8.  Indomethacin 
C19H16ClNO4
 
357.79 151-155 0.94 µg/ml at 25°C 106)
9.  Glibenclamide 
C23H28ClN3O5S 
 
494.01 168-172 5.9 µg/ml  at 22°C 109)
10. Nitrazepam 
C15H11N3O3
 
 
281.27 224-225 77 µg/ml at 25°C 106)
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 Drug Chemical structure Molecular weight 
Melting 
point (°C) Water solubility 
11. Mefenamic acid 
C15H15NO2
 
241.29 230-231 20 µg/ml at 30°C 106)
12. Albendazole 
C12H15N3O2S 
 
265.33 209 0.16 µg/ml at 25°C 110)
13. Flufenamic acid 
C14H10F3NO2
 
281.23 132-135 9.1 µg/ml at 25°C 106)
14. Carbamazepine 
C15H12N2O 
236.28 190-192 18 µg/ml at 25°C 106)
15. Phenylbutazone 
C19H20NO2 
308.37 105-106 48 µg/ml at 30°C 106)
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 Drug Chemical structure Molecular weight 
Melting 
point (°C) 
Water 
solubility 
16. Tolbutamide 
C12H18N2O3S 
 
270.35 127-128 109 µg/ml at 37°C 106)
17. Flurbiprofen 
C15H13FO2
 
244.26 113-114 8 µg/ml at  22°C 106)
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SO O
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Polyvinylpyrrolidone (PVP)
Nonionic water-soluble polymer 
PVPK17   M.W. 10,000
Molecular weight of monomer: 111
Melting point: soften at 150℃
Very hygroscopic
Sodium dodecyl sulphate (SDS)
Anionic surfactant
MW : 288.38
Melting point:  204-207℃
Critical micelle concentration (CMC) at 20ºC: 8.2 mM (2.4 mg/ml) 55)
N
CH
O
CH2
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Fig. 1-1  Chemical structures and physicochemical properties of the pharmaceutical 
excipients used in this study 
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Fig. 1-2  Photographs of the suspensions obtained from probucol/PVP K17/SDS 1:3:1 PM 
and GM  
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Table 1-2  Mean particle size of the micronized drug particles obtained from 
drug/PVP K17/SDS ternary GM* after dispersing into distilled water 
 
Mean particle size (nm) 
Drugs 
After dispersion After storage for 4 h 
Probucol 90 97 
Piroxicam 97 98 
Reserpine 101 111 
Phenytoin 136 137 
Griseofulvin 133 144 
Nifedipine 134 153 
Furosemide 142 144 
Indomethacin 143 167 
Glibenclamide 175 178 
Nitrazepam 168 309 
Mefenenamic acid 172 317 
Albendazole 158 396 
Flufenamic acid 413 424 
Carbamazepine 360 483 
Phenylbutazone 511 564 
Tolbutamide 461 >2µm 
Flurbiprofen 1622 >2µm 
* Drug:PVP K17:SDS, 1:3:1 w/w/w, ground for 30 min 
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The suspensions of nine drugs (from probucol to glibenclamide in Table 1-2) possessing 
particle size in the range 90-180 nm, exhibited good stability after storage for 4 h.  In 
addition, the suspension containing flufenamic acid was also stable after storage though 
the initial particle size was relatively large.  The mean particle size of the suspensions of 
the other six drugs was increased after storage, indicating aggregation of fine particles.  
Since small-size particles in the suspension are thermodynamically unstable due to their 
large surface area, the small particles in those systems tend to reduce the surface free 
energy in order to reach a more thermodynamically stable state by formation of 
agglomerates.  The drug/PVP/SDS ternary system could contribute to stabilize the 
suspension with nanoparticles.  However, optimization of experimental conditions, such as 
type and mixing ratio of polymer and surfactant as well as the grinding time, should be 
required to obtain stable nanosuspensions of these drugs.  From the results, drug/PVP/SDS 
ternary GM was applicable for most of the poorly water-soluble drugs.  
 For further understanding of the stability and mechanism of drug nanoparticle 
formation, phenytoin, probucol and griseofulvin were used. 
 
2. Stability studies 
 Generally, fine particles in suspensions are thermodynamically unstable due to 
their high energetic state.  Many attempts to stabilize the system have been performed to 
obtain practically stable nanosuspensions for pharmaceutical use 17, 34-41).  
 To evaluate the stability of drug nanoparticles in physiological condition, JP 
XIV first fluid (pH 1.2) and JP XIV second fluid (pH 6.8), were employed as dispersing 
media (Table 1-3).  When the ternary GMs were dispersed into water, the obtained 
nanoparticles showed narrow range unimodal distributions in all systems (Fig. 1-3).  The 
mean volumetric particle sizes of the suspensions obtained from phenytoin, probucol and 
griseofulvin ternary GMs dispersed into water were 136, 90 and 133 nm respectively, and 
these values were almost constant after storage at 25°C for 4 h (Table 1-3).  The 
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Table 1-3  Mean particle size of the micronized drug particles obtained from 
drug/PVP K17/SDS ternary GM* after dispersion into distilled water (DW), JP 1st fluid 
and JP 2nd fluid 
 
Mean particle size (nm) 
Suspensions from ternary GMs 
After dispersion After storage for 4 h 
Phenytoin/PVP K17/SDS   
               in DW 136 137 
               in JP 1st fluid 133 124 
               in JP 2nd fluid 100 112 
Probucol/PVP K17/SDS   
               in DW 90 97 
               in JP 1st fluid 82 109 
               in JP 2nd fluid 93 79 
Griseofulvin/PVP K17/SDS   
               in DW 133 144 
               in JP 1st fluid 149 171 
               in JP 2nd fluid 137 166 
* Drug:PVP K17:SDS, 1:3:1 w/w/w, ground for 30 min 
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Fig. 1-3  Particle size distribution patterns of the suspensions obtained from ternary 
ground mixtures (drug/PVP K17/SDS at a weight ratio of 1:3:1):  
(A) Phenytoin, (B) Probucol, (C) Griseofulvin 
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suspensions dispersed into JP first and second fluids also exhibited the same appearance as 
those dispersed into distilled water.  Regardless of the dispersion media, all ternary GMs 
of phenytoin, probucol and griseofulvin provided a stable nanosuspension of comparable 
mean particle size.  Among the three drugs, probucol exhibited the smallest particle 
formation.  The particle size generated in JP first fluid was generally larger than that in JP 
second fluid.  These results were considered to be due to the ionization effect of weak 
acidic drugs in different pH.  The study suggested that the ternary GM of the drug with 
PVP and SDS would enhance the dissolution owing to the fine particle formation in 
gastrointestinal tracts. 
 The long-term stability of the suspensions obtained from ternary GMs was 
evaluated by particle size analysis and quantitative determination.  Particle size analysis 
revealed that the mean particle size was still less than 250 nm even after storage for 28 
days (Fig. 1-4).  Quantitative analysis showed that the amount of drug as nanoparticles 
(<0.8 µm) in the 28 day-stored suspensions of probucol and griseofulvin was more than 
96%.  In the case of phenytoin system, the particle size slightly increased due to particle 
aggregation and/or agglomeration.  However, the particle size was still in the range of the 
submicron region even after storage for 28 days.  HPLC chromatograms of the drugs in 
the suspensions after storage for 28 days did not show any difference from those of the 
intact suspensions, and this indicated that the drugs in the suspensions were chemically 
stable.  These results suggested that the change in the amount of the drug fine particles in 
28 day-stored suspensions was extremely small, and the suspensions obtained from the 
ternary ground mixture would be practically stable for at least one month.  From the 
results of these stability tests, this formulation seemed applicable to the oral administration 
of poorly water-soluble drugs to enhance the bioavailability. 
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Fig. 1-4  Changes in the mean particle size (full symbols) and the amount of fine drug 
particles (<0.8 µm) (empty symbols) of the suspensions obtained from the ternary ground 
mixtures with storage time 
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3. Effect of additives on nanoparticle formation 
 In order to estimate the mechanism of nanoparticle formation, it is essential to 
investigate the effect of additives (PVP and SDS) on the nanoparticle formation.  
Experiments for ground mixtures of the drug-additive binary system (drug/PVP K17 1:3 
w/w and drug/SDS 1:1 w/w), the particle size analysis and the quantitative determination 
were conducted for comparison with the results of the ternary systems (drug/PVP 
K17/SDS, 1:3:1 w/w/w).  
 The amount of the drug existing as nanoparticles in the suspension was 
determined by HPLC (Fig. 1-5).  Quantitative determination revealed that 93 - 98% of the 
drug in the ternary GM system existed as nanoparticles smaller than 0.8 µm.  On the other 
hand, only 0.4-10% was found as nanoparticles in binary GM systems, except for 
phenytoin/PVP (1:3 w/w) binary GM (21%) and griseofulvin/SDS (1:1 w/w) binary GM 
(43%).  The amount of drug found in the filtrate obtained by filtration through a 0.2 µm 
membrane filter was only 8.6 % for phenytoin/PVP (1:3 w/w) binary GM and 4.6 % for 
griseofulvin/SDS (1:1 w/w) binary GM whereas that found in the filtrate obtained from 
the ternary GM of phenytoin and griseofulvin was 74.1 % and 53.6 % respectively.  The 
amount of nanoparticles (<0.2 µm) significantly decreased in binary systems, and these 
results supported the idea that the ternary GM was essential in the formation form 
nanoparticles of 200 nm or less.  Results of the mean particle size measurements also 
indicated that the binary systems provided the suspensions with remarkably large sizes of 
particles comparatively with the ternary systems (Table 1-4).  It was estimated that the 
drug-additive binary system had limiting effectiveness for micronization while the 
combined use of both PVP K17 and SDS played an important role in the nanoparticle 
formation of drugs.  Furthermore, mean particle size of the binary mixtures apparently 
increased by dispersing into JP first fluids.  Molecular interaction between PVP and SDS 
would be another significant factor for stable drug nanoparticle formation.  Esumi et al. 
reported the PVP-SDS complex formation into solutions and at particle surfaces 96, 99). 
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Table 1-4  Mean particle size of the micronized drug particles obtained from binary 
ternary GMs* after dispersion into distilled water 
 
Mean particle size (nm) 
Suspensions from binary and ternary GMs 
phenytoin probucol griseofulvin
   Drug/PVP K17, 1:3 w/w 1636 3082 2905 
   Drug/SDS, 1:1 w/w 563 842 294 
   Drug/SDS, 1:1 w/w 
   (dispersed into JP 1st fluid) 610 2049 598 
   Drug/PVP K17/SDS, 1:3:1 w/w/w 128 81 133 
* Grinding time 30 min 
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In the case of this study, the PVP-SDS complex would be easily formed by grinding, and it 
contributes to the drug nanoparticle formation. 
 
4. Crystalline state characterization by PXRD 
 To investigate the surface state of the ternary GM, PXRD measurements were 
performed.  Fig. 1-6 shows PXRD patterns of phenytoin/PVP K17/SDS systems.  The PM 
showed characteristic X-ray diffraction peaks of both phenytoin and SDS crystals (Fig. 1-
6 (C)).  The ternary GM of phenytoin with PVP and SDS exhibited halo patterns, 
indicating that phenytoin was transformed into an amorphous state (Fig. 1-6 (D)).  Nair et 
al. 53) reported that the interaction of the drug with PVP might change the physical state of 
the drug, from crystalline to amorphous.  Nakai et al. 111) reported that grinding caused 
extremely small sizes of crystallite or micro-assemblies of the molecules, and these small 
particles surrounded by additives did not clearly show the diffraction peaks on the X-ray 
diffractogram.  The expression ‘X-ray amorphous’ was used in some articles when the 
PXRD showed entirely a halo pattern 112, 113).  In this experiment, the crystallinity of the 
drug in the GM was remarkably decreased by the mechanical stress during grinding.  The 
solid state of the drug in the GM might be consisted as the amorphous and/or fine 
crystallite of the drug. 
 To investigate the surface state of drug nanoparticles after dispersing into water, 
PXRD measurement of the dispersed particles collected by ultracentrifugation was 
performed (Fig. 1-6 (E)). The sediment of phenytoin co-ground mixture showed the 
characteristic diffraction peaks of phenytoin crystals, indicating that the drug in the 
particles dispersed into water existed at a crystalline state.  
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Fig. 1-6  PXRD patterns of phenytoin/PVP K17/SDS systems:  
(A) phenytoin intact, (B) ground mixture of PVP K17/SDS (weight ratio 3:1), (C) physical 
mixture of phenytoin/PVP K17/SDS (weight ratio 1:3:1), (D) ground mixture of 
phenytoin/PVP K17/SDS (weight ratio 1:3:1), (E) phenytoin particles sediment collected 
by ultracentrifugation 
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5. Zeta potential measurement 
 Nanoparticles obtained from ternary GMs were stable in the dispersing media.  
In order to understand the mechanisms of dispersion of solid particles, the effects of the 
polymer and surfactant on the surface electrical charge of the suspended drug particles 
were characterized by the zeta potential measurement.  The results of the zeta potential 
measurement are shown in Fig. 1-7.  Without additives, drugs exhibited their own negative 
charge with the magnitude of the zeta potential between -18 and -26 mV.  When the drug 
was co-ground with PVP, the magnitude of negative values decreased in each system.  
This would be due to the adsorption of PVP onto the particles.  For the zeta potential of 
the drug/PVP/SDS ternary co-ground systems, the magnitude of the negative charge 
gradually increased with the increase of the weight ratio of SDS.  These results suggest 
that stabilization of the suspension resulted from the adsorption of both PVP K17 and SDS 
onto drug particles.  Terayama et al. studied the aqueous dispersion behavior of CT112 
particles using a water-soluble polymer and a surfactant 102, 103).  They reported that mixed 
systems of cellulose and SDS provided a stable aqueous dispersion of CT112 more 
effectively than using only cellulose or SDS alone.  Zeta potential and quantitative 
adsorption data revealed that dispersion stability was enhanced due to the adsorption of 
both polymer and surfactant on drug particles.  They also reported that the polymer might 
act as a protective colloid, consequence of a high steric hindrance between the adsorbed 
polymer layers, while adsorbed SDS controlled the nucleation process of the drug and 
caused an electrostatic repulsion force between drug particles.  In the case of this study, 
preparation procedure of the drug particles is different.  However, the role of PVP and 
SDS for the drug nanoparticle formation would be similar as that of CT112. 
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Fig. 1-7  Effect of PVP and SDS on the zeta potential of dispersed drug particles   
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6. Mechanism of the stabilization of drug nanoparticles 
 From these results, the mechanism of stable nanosuspension would be 
considered to proceed as follows: when the ternary GM was dispersed into distilled water, 
the fine crystalline and/or amorphous drug gathered and/or crystallized in the medium 
immediately, the growth of the drug particle size was rapidly prevented by the adsorption 
of PVP on the surface through hydrophobic interaction and stabilized by the anionic 
surfactant, SDS, through electrostatic repulsion.  A complex formation between PVP and 
SDS would also be an important factor for the nanoparticle formation, as nanoparticles 
were not formed in the binary GMs.  Consequently, the particle size of drugs in the 
suspension remained constant for long time due to the inhibitory effect of agglomeration 
by both PVP and SDS. 
 
7. Solid-state stability study  
 The effect of the storage condition of GM on the powder properties was 
investigated.  Powder X-ray diffraction pattern of probucol/PVP K17/SDS ternary GM did 
not change after storage at 40ºC, RH 22% for 6 months (Fig. 1-8).  Particle size analysis 
demonstrated that the particle size distribution pattern and the mean particle size (92 nm) 
of the stored GM after dispersing into water were almost same as that before storage (Fig. 
1-9).  These results indicated that probucol/PVP K17/SDS ternary GM was stable under 
the conventional storage conditions.    
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Fig. 1-8  PXRD patterns of probucol/PVP K17/SDS (weight ratio 1:3:1): 
(A) Probucol intact, (B) Probucol/PVP K17/SDS PM, (C) Probucol/PVP K17/SDS GM 
after grinding, (D) Probucol/PVP K17/SDS GM after storage at 40ºC, RH 22% for 6 
months 
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Fig. 1-9  Changes in particle size distribution patterns of probucol/PVP K17/SDS GM 
dispersed into distilled water  
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CHAPTER II 
Molecular interaction among components of  
the probucol/PVP/SDS ternary system investigated by solid-state NMR 
 
1. Particle size analysis 
 In this study, the effect of the PVP molecular weight on nanoparticle formation 
was investigated.  Four kinds of PVP with different molecular weight were used to prepare 
the ternary GMs.  The mixing weight ratio of the drug/PVP/SDS was determined as 1:3:1 
because this ratio showed the smallest nanoparticle formation with the least amount of 
additives 104).  The mean particle size of GMs, after their dispersion into distilled water, is 
shown in Table 2-1.  The particle size distributions of the suspensions obtained from the 
ternary GMs are shown in Fig. 2-1.  Probucol nanoparticles could be obtained when the 
low molecular weight PVP (PVP K12, PVP K17, and PVP K30) was used as co-grinding 
additives, while PVP K90 did not show the nanoparticle formation.  The size reduction 
effectively occurred as the molecular weight of PVP decreased.  Moreover, the required 
grinding time for nanoparticle formation depends on the molecular weight of PVP.  These 
results might reflect the magnitude of interactions of the drug with additives, since the 
bulky PVP K90 shows no nanoparticle formation.  For further understanding of the 
interaction and mechanism of the drug nanoparticle formation, the physicochemical 
properties of the ground mixtures were characterized by powder X-ray diffraction (PXRD), 
and solid-state cross polarization and magic angle spinning (CP/MAS) 13C-NMR 
spectroscopy. 
 
2. Solid-state characterization by PXRD 
 The PXRD patterns of pharmaceutical excipients used in this study are shown in 
Fig 2-2.  The binary ground mixture of PVP K17 and SDS (Fig. 2-2 (D)) indicates that the 
characteristic diffraction peaks at 2θ = 2.2, 4.4, 6.7, 20.4 and 21.7, were the same as the 
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Table 2-1   Mean particle size of probucol nanoparticles obtained from ternary ground 
mixtures of probucol/PVP/SDS 1:3:1 after dispersion into distilled water.  Samples were 
measured by UPA (0.003-6 µm). 
 
Mean particle size ± S.D. 
Ternary ground mixture 
Ground for  
15 min 
Ground for 
30 min 
Ground for 
60 min 
Probucol/PVP K12/SDS 79 ± 9.2 16 ± 1.3 14 ± 1.7 
Probucol/PVP K17/SDS 125 ± 1.8 90 ± 1.5 64± 4.7 
Probucol/PVP K30/SDS 763 ± 7.4 150 ± 6.6 65 ± 6.2 
Probucol/PVP K90/SDS* 9706 ± 16.7 5279 ± 11.9 3934 ± 71.6 
  (181 ± 3.8**)  
S.D.: standard deviation, n = 3 
* Samples were measured by FRA (0.1-700 µm). 
** Samples were prepared by grinding probucol with freeze-dried PVP K90/SDS. 
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Fig. 2-1  Particle size distribution patterns of probucol nanoparticles obtained from ternary 
ground mixtures of probucol/PVP/SDS 1:3:1 after dispersing into distilled water: 
(A) Ground mixture with PVP K12, (B) PVP K17, (C) PVP K30, (D) PVP K90, (E) 
probucol ground with freeze dried PVP K90/SDS.  Samples (A), (B), (C) and (E) were 
measured by UPA (0.003-6 µm).  Sample (D) was measured by FRA (0.1-700 µm).  
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Fig. 2-2  PXRD patterns of pharmaceutical excipient used in this study:  
(A) PVP K17, (B) SDS, (C) Physical mixture of PVP K17/ground SDS (3:1), (D) Ground 
mixture of PVP K17/SDS (3:1).  The grinding time was 30 min. 
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PXRD pattern of the PVP/ground SDS physical mixture (Fig. 2-2 (C)).  The characteristic 
diffraction peaks observed in PVP K17/SDS ground mixture resulted from the diffraction 
peaks of SDS after grinding.   
 Fig. 2-3 shows X-ray diffraction patterns of probucol/PVP/SDS systems.  
Probucol intact (stable form I) transformed into metastable form II after grinding (Fig. 2-3 
(A), (B)).  The ternary PM showed characteristic X-ray diffraction peaks of both probucol 
crystals and SDS crystals (Fig. 2-3 (C)).  No diffraction peak of probucol was observed in 
the ternary GMs of probucol with PVP and SDS, except for the GM prepared with PVP 
K90, indicating an X-ray amorphous state of probucol when ground with PVP K12, K17 
and K30.  Co-grinding probucol with a low molecular weight PVP would be preferable in 
promoting the interaction between probucol and PVP as has been reported by Broman et al. 
50).  Grinding caused extremely small sizes of crystallite or micro-assemblies of molecules 
but these small particles surrounded by the additives did not clearly show the diffraction 
peaks on the X-ray diffractogram 111).  It was speculated that probucol molecules also exist 
in an amorphous state and/or as crystallite.  On the other hand, ternary ground mixtures 
with a high molecular weight PVP K90 exhibited the diffraction peaks of polymorphic 
form II of probucol (Fig. 2-3 (G)).  Probucol in the ternary GM with PVP K90 
transformed itself into polymorph form II by grinding.  Molecular interaction between 
probucol and PVP K90 occurred on grinding with difficulty. 
 
3. Solid-state characterization by 13C CP/MAS NMR spectroscopy 
 3.1 13C CP/MAS NMR spectra of probucol, ground probucol, PVP and SDS 
 Chemical structures and 13C CP/MAS NMR spectra of probucol, PVP and SDS 
are shown in Figs. 2-4 and 2-5, respectively.  The solid-state 13C spectrum of each 
component was assigned on the basis of the solution 13C NMR spectra and literature data 
for similar systems 66, 75, 114).  The intact probucol exhibited the resonance peak of the 
hydroxyl-substituted carbon in the phenolic ring (C-6) at 154.9 ppm.  Probucol 
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Fig. 2-3  PXRD patterns of ternary ground mixtures of probucol/PVP/SDS (1:3:1) and the 
related materials:  
(A) Probucol intact, (B) Ground probucol, (C) Physical mixture of probucol/PVP 
K17/SDS, (D) Ternary ground mixture with PVP K12, (E) PVP K17, (F) PVP K30, (G) 
PVP K90.  The grinding time was 30 min. 
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Fig. 2-4  Chemical structure of probucol, PVP and SDS.  The numbering of the carbon 
atoms in the above structures correspond to that in Figs. 2-5, 2-6, 2-7, 2-8, 2-10 and 2-12 
for 13C CP/MAS NMR spectra. 
 
 
 
 47
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 48
polymorphs of forms I and II can be distinguished using 13C CP/MAS NMR spectra.  A 
characteristic resonance peak of probucol form II was found at 117.4 ppm.  This resonance 
in NMR spectra would be arising from the conformational changes, since the chain of C-
S-C-S-C at the center of the probucol molecules extended and had a molecular symmetry 
in form I, but the latter were lost in form II 105). 
 3.2 Solid-state interaction in the ternary ground mixture of 
probucol/PVP/SDS  
 Figure 2-6 shows 13C spectra of the ternary PM and GM with four kinds of PVP.  
The 13C spectra are especially focused on two regions: hydroxyl carbon (C-6) and aromatic 
carbon of probucol (C-3 to C-5) in the range 110-165 ppm, and sulfate carbon of SDS (C-
1") in the range 60-80 ppm.  The spinning sidebands of the resonance peak of the aromatic 
carbon (C-4) of probucol and the carbonyl carbon (C-6') of PVP were depicted as stars 
with the corresponding carbon numbers.  The spectrum of the ternary PM shows no 
significant interaction among probucol, PVP and SDS.  The C-6 resonance of probucol 
(around 155 ppm) in the ternary GM with PVP K12, 17 or 30 exhibited a peak broadening.  
When the wave separation was performed using computer-fitted curves (ALICE2 software, 
JEOL, Japan), it was found that the obtained curves consisted of two components: the 
downfield shifted peak resulted from the probucol-PVP interaction (155.7 ppm), and an 
original peak of probucol crystals (154.9 ppm).  This shift was consistent with the 
formation of a hydrogen bonding interaction between the drug hydroxyl group and 
carbonyl group of PVP 50, 114).  The intensity of the resonance from probucol-PVP 
interaction increased in the order of PVP K30 < K17< K12, whereas the downfield shift 
was not observed in the ternary GM with PVP K90.  A new broad peak around 143 ppm 
(◊), arising from changes in the resonance of aromatic carbon of probucol, was observed 
in the GMs with PVP K12, K17, and K30.  On the contrary, the ternary GM prepared with 
PVP K90 did not show a new broad peak around 143 ppm, it however exhibited a new 
characteristic peak of probucol form II at 117.3 ppm.  Interestingly, the ternary GM with 
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PVP K30 obviously shows the form II peak that could not be detected in PXRD patterns.  
These results showed that solid-state NMR spectroscopy had an advantage in the detection 
of the polymorphic transition of probucol crystals in the microenvironment.   
 With respect to the NMR resonance from SDS carbons, the ternary PM 
exhibited the characteristic signals from the C-1" carbon of SDS at 68.3 ppm.  The ternary 
GMs showed a shoulder peak.  The curve fitting revealed that the shoulder peak was 
caused by the upfield shift from 68.3 to 66.7 ppm resulting from the PVP-SDS interaction.  
Complexation of PVP and SDS both through electrostatic and hydrophobic interactions in 
aqueous solutions was reported by many authors 63-76).  The electrostatic interaction should 
exist between the negatively charged SDS head group and the nitrogen atom on the 
pyrrolidone ring 115).  Roscigno et al. also reported that the electrostatic interaction was 
assisted by the attractive interaction between the negatively charged PVP oxygen 
(N+=C−O-) and the electron poor C-1” of sodium decyl sulfate 75).  The highfield shift of 
the resonance of SDS decreased when the molecular weight of PVP increased.  As 
molecular weight of PVP represented the chain size of polymer, the quantity of terminal 
groups of PVP increased when the molecular weight of PVP was low 62).  Thus, the 
interactions during grinding were better for the system of the lower molecular weight PVP 
than that of the higher one, due to easy access of probucol and SDS within the polymer.  
These results were consistent with a previous study that the lower molecular weight PVP 
would have greater effects on the interactions of ibuprofen-PVP and piroxicam-PVP 49, 62). 
 The results from the solid-state 13C NMR spectra indicated that the interactions 
of both probucol-PVP and PVP-SDS increased with the decrease of PVP molecular weight 
(PVP K90 < PVP K30 < PVP K17 < PVP K12).  It was suggested that grinding-induced 
interactions brought about the achievement of molecular dispersion.  As the greatest extent 
of interactions was found in the ternary GM prepared with PVP K12, the smallest 
nanoparticles would be obtained.  Particle size analysis demonstrated that the size of 
probucol nanoparticles obtained from the probucol/PVP K12/SDS GM was significantly 
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reduced to 16 nm.  Smaller nanoparticles were obtained from the ternary GM of PVP K17 
and PVP K30 when the experiments were conducted at the optimum conditions such as 
ternary composition and grinding time.  As shown in Table 2-1, when the grinding time 
was increased to 60 min, an effective particle size reduction to approximately 65 nm could 
be achieved from the ternary ground mixtures with PVP K17 and K30. 
 3.3 Solid-state interaction in the binary ground mixture of probucol/PVP  
 Figure 2-7 shows PXRD patterns of probucol/PVP binary GMs.  PXRD peaks 
of probucol were not observed by co-grinding.  This indicated that probucol was 
transformed into an amorphous state by grinding with PVP.  It has been reported that 
interactions of the drug with polymer induced drug amorphization 47).  Molecular 
interactions occurred between probucol and PVP were investigated by solid-state NMR 
(Fig. 2-8).  The NMR spectrum of the binary PM was identical to the superposition of 
probucol and PVP.  All GMs exhibited the same changes in NMR spectra regardless of the 
PVP molecular weight.  The NMR spectra of probucol in all binary GMs show a peak 
broadening and the downfield shift of the hydroxyl carbon together with the new broad 
NMR peak at around 143 ppm.  No resonance of probucol polymorph form II was 
observed. 
 It should be pointed out that a color change induced by mechanical stress was 
observed.  The ternary GMs prepared from PVP K12, PVP K17 and PVP K30 and also all 
the binary GMs of probucol/PVP produced a pink colored powder after grinding.  These 
phenomena would be related to the appearance of a new broad resonance peak at around 
143 ppm.  No color change was observed for the ternary GM prepared from PVP K90, 
which did not show the new NMR peak at around 143 ppm and nanoparticle formation.  
HPLC quantitative analysis confirmed that this kind of changes did not derive from a 
chemical decomposition of probucol.  After GMs were dispersed into distilled water, 
suspensions did not display a pink color, indicating a reversible color change.  Sheth et al. 
reported that, under mechanical stress, the colorless crystal piroxicam became yellow at 
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Fig. 2-7  PXRD patterns of the binary ground mixture of probucol/PVP (1:3):  
(A) Physical mixture with PVP K17, (B) Binary ground mixture with PVP K12, (C) PVP 
K17, (D) PVP K30, (E) PVP K90.  The grinding time was 30 min.  
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Fig. 2-8  13C CP/MAS NMR spectra of the binary ground mixture of probucol/PVP (1:3): 
(A) Physical mixture with PVP K17, (B) Binary ground mixture with PVP K12, (C) PVP 
K17, (D) PVP K30, (E) PVP K90.  Diamonds represent the new peaks observed. 
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the amorphous state due to charged piroxicam molecules formed by the intermolecular 
proton transfer 115).  Although it is difficult to clarify the reason for pink coloration, the 
color change under mechanical stress might be associated with the solid-state disorder of 
probucol molecules at the particle surface, as a consequence of the solid-state interaction 
between the hydroxyl of probucol and the carbonyl of PVP induced by grinding. 
 3.4 Solid-state interaction in the binary ground mixture of probucol/SDS  
 Figure 2-9 shows PXRD patterns of the probucol/SDS binary system.  The 
binary ground mixture of probucol/SDS exhibited diffraction peaks of polymorph form II 
of probucol (Fig. 2-9 (D)).  In consistency with PXRD results, the 13C spectrum of the 
ternary GM of probucol/SDS also demonstrated the characteristic resonance peak of 
probucol polymorph form II at 117.4 ppm (Fig. 2-10).  The spectrum of probucol/SDS 
GM was a superposition of the spectra of probucol/ground SDS PM, indicating that there 
was no interaction between probucol and SDS.   
 3.5 Solid-state interaction in the binary ground mixture of PVP/SDS  
 Figure 2-11 shows PXRD patterns of the PVP/SDS binary system.  
Characteristic SDS diffraction peaks were observed in the GM prepared with PVP K17, 
PVP K30 and PVP K90.  The X-ray diffraction intensity of SDS increased with the 
molecular weight of PVP.  It was clear that, the binary GM with PVP K12 exhibited a halo 
pattern without any peak of SDS.  The GM prepared with the low molecular weight PVP 
was likely to induce the interaction of SDS with PVP, resulting in changes of the physical 
state of SDS to an amorphous state.  Interactions between additive components might play 
a key role in nanoparticle formation due to their ability to stabilize the nanoparticles.  
Further investigations to clarify the interaction between PVP and SDS were employed 
using solid-state NMR spectroscopy. 
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Fig. 2-9  PXRD patterns of the binary ground mixture of probucol/SDS (1:1):  
(A) Probucol intact, (B) Ground probucol, (C) Physical mixture of probucol/SDS, (D) 
Binary ground mixture of probucol/SDS.  The grinding time was 30 min.  
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Fig. 2-11  PXRD patterns of the binary ground mixture of PVP/SDS (3:1):  
(A) Physical mixture with PVP K17, (B) Binary ground mixture with PVP K12, (C) PVP 
K17, (D) PVP K30, (E) PVP K90.  The grinding time was 30 min. 
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 Changes in the chemical shift of 13C NMR spectra of the carbon near the head 
group (C-1") of SDS are shown in Fig. 2-12.  The curve fitting revealed the upfield shift 
of the C-1" carbon from 68.3 to 66.7, which should be resulting from the interaction 
between PVP and SDS.  The magnitude of the upfield shift was in the order: PVP K12 > 
PVP K17 > PVP K30 > PVP K90.  Changes in the chemical shift had the same trend as 
results of the ternary GM.  PVP of low molecular weight better induced the interaction 
with SDS in solid-state on grinding since the binary ground mixture with PVP K12 
showed a stronger interaction than the GMs prepared with high molecular weight PVP 
(K17, K30 and K90).   
 
4. Nanoparticle morphology 
 SEM images of probucol/PVP K12/SDS and probucol/PVP K17/SDS ternary 
GMs are represented in Fig. 2-13.  It is interesting to note that the agglomerates were 
composed of spherical nanoparticles with extremely small size of 15-25 nm and 30-50 nm 
for ternary GMs prepared with PVP K12 and PVP K17 respectively.  In consistency with 
PXRD results, the halo pattern of probucol in the ternary GM could be due to the 
existence of the crystallite of probucol.  The SEM image obviously showed the formation 
of the assemblies of drug nanocrystals in the ternary GM induced by grinding.  The mean 
particle size of probucol in the suspension was 16 nm (Table 2-1), suggesting that the 
agglomeration of the dispersed probucol nanocrystals was inhibited due to the adsorption 
of PVP and SDS onto the particle surface.   
 
5. Effect of ternary composition on drug nanoparticle formation 
 From the results of the binary system, it was found that probucol interacted with 
PVP regardless of the PVP molecular weight.  On the other hand, the interaction between 
PVP and SDS increased with the decrease of the molecular weight of PVP.  Low 
molecular weight PVP interacted effectively with SDS due to the high proportion of the 
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Fig. 2-12   13C CP/MAS NMR spectra of the binary ground mixture of PVP/SDS (3:1): 
(A) Physical mixture with PVP K17, (B) Binary ground mixture with PVP K12, (C) PVP 
K17, (D) PVP K30, (E) PVP K90  
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Fig. 2-13   SEM micrographs of probucol nanoparticles prepared from the ternary ground 
mixture of probucol/PVP/SDS (1:3:1):  
(A) Probucol/PVP K12/SDS (200,000 X), (B) Magnification of (A) (5,000,000 X) 
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Fig. 2-13 (cont.)  SEM micrographs of probucol nanoparticles prepared from the ternary 
ground mixture of probucol/PVP/SDS (1:3:1):  
(C) Probucol/PVP K17/SDS (200,000 X), (D) Magnification of (C) (5,000,000 X) 
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number of polymer chains and the quantity of terminal groups of PVP providing an access 
into polymer matrix.  PXRD patterns demonstrated that the binary GM of SDS with PVP 
K12 was transformed into an amorphous state, while that with PVP K17 and K30 showed 
diffraction peaks of SDS (Fig. 2-11).  Table 2-2 shows the mean particle size of probucol 
nanoparticles when the ternary PMs of probucol/PVP K12/SDS are ground at various SDS 
weight ratios: 1:3:0.3, 1:3:0.4, 1:3:0.5, 1:3:1, 1:3:2 and 1:3:3.  A SDS ratio of at least 0.4 
(1:3:0.4) was necessary to produce nanometer-sized particles.  Ratios from 1:3:0.5 to 1:3:1 
were the most appropriate due to the achievement of the reduction of the particle size to 20 
nm, which showed a halo pattern of SDS in the PXRD.  In the GMs 1:3:2 and 1:3:3, the 
mean particle size of probucol increased when the excess amount of SDS crystals 
remained in the system, which showed the characteristic diffraction of SDS crystals in the 
PXRD.  The solid-state interaction between PVP and SDS definitely played a key role in 
the nanoparticle formation; however, the excess amounts of SDS crystals, which did not 
interact with PVP, could obstruct the interaction between drug and polymer during the 
grinding process.   
 The accessibility of SDS into polymer matrix at solid state was more difficult 
for the high molecular weight PVP as shown in the GM with PVPK90.  In order to solve 
this problem, a PVP K90/SDS solid dispersion prepared by freeze-drying method was 
used.  PVP K90 and SDS (3:1) were dissolved into small amounts of water then freeze-
dried before the grinding with probucol.  NMR spectra of the ternary GM of probucol with 
freeze-dried PVP K90/SDS showed different results from that shown in Fig. 2-6.  As 
illustrated in Fig. 2-14, the resonance of SDS in the ternary GM clearly moved upfield 
from 69.1 to 68.3 ppm due to PVP-SDS interactions, showing that a higher accessibility of 
SDS into PVP K90 was achieved by freeze-drying.  The resonance of probucol in the 
ternary GM also moved downfield from 154.9 to 155.7 ppm, indicating a significant 
interaction between probucol and PVP K90.  Moreover, an effective size reduction till 181 
nm was successfully obtained from the ternary GM of probucol with the freeze-dried  
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Table 2-2  Mean particle size of the probucol nanoparticles obtained from ternary GMs* 
of probucol/PVP K12/SDS 1:3:Y after dispersion into distilled water 
 
SDS weight ratio (Y) in the ternary GM of 
probucol/PVP K12/SDS 1:3:Y Mean particle size (nm) ± S.D. 
0.3 > 1 µm 
0.4 > 500 nm 
0.5 25 ± 9.1 
1.0 16 ± 1.3 
1.5 68 ± 3.0 
2.0 126 ± 3.6 
3.0 131 ± 2.8 
S.D.: standard deviation, n = 3 
* Grinding time 30 min 
 64
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 65
PVP K90/SDS (Table 2-1, Fig. 2-1).  These results indicated that the increase in the 
accessibility of SDS to the PVP polymer by freeze-drying could enhance the interactions 
between them.  
 The effect of PVP/SDS binary compositions on nanoparticle formation was 
investigated by varying the weight ratio of PVP (X = 1, 2, 3, 4) and SDS (Y = 0.5, 1.0, 
1.5) in the probucol/PVP K12/SDS (1:X:Y) ternary GM.  The mean particle size of each 
system is shown in Fig. 2-15.  Fig. 2-15 (A) demonstrated that the mean particle size of 
the GM prepared at a ratio of 1:1:0.5 or 1:2:0.5 was remarkably large (600-650 nm) in 
comparison with the other additive ratios.  An effective size reduction to less than 100 nm 
was observed when the ratio of PVP (X) was more than 3.  The nanoparticle formation 
was not observed when the weight ratios of PVP were X = 3 and 4, and the weight ratio of 
SDS (Y) was reduced to Y = 0.3 (Fig. 2-15 (B)).  A minimum weight ratio of SDS at 0.4 
should be required to produce the nanometer-sized particles.     
     
6. Possible interaction among components in the ternary ground mixture 
 The possible interactions among the components of the ternary GM are 
illustrated in Fig. 2-16.  13C NMR studies revealed that, the grinding induced solid-state 
interactions of probucol-PVP and PVP-SDS.  Probucol seemed to interact with PVP 
through hydrogen bonding between the hydroxyl of probucol and the carbonyl of PVP.  An 
electrostatic interaction should exist between the negatively charged head group of SDS 
and the nitrogen atom on the pyrrolidone ring of PVP 66).  In the ternary GM, the 
interactions of either probucol-PVP or PVP-SDS were accelerated with the decrease in the 
PVP molecular weight.  These interactions contributed to the effective size reduction and 
production of the nanocrystal of the drug. 
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Fig. 2-15  Effect of weight ratio of PVP K12 (X) and SDS (Y) on nanoparticle formation 
of probucol/PVP K12/SDS (1:X:Y) 
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CHAPTER III 
Speculation on the mechanism of  
grinding-induced nanoparticle formation 
 
 The results in chapter one demonstrated that co-grinding of a drug with PVP and 
SDS could be applicable to many kinds of poorly water-soluble drugs since almost 
drug/PVP/SDS ternary GMs lead to the formation of drug nanoparticles.  Solid-state 13C 
NMR results in chapter two revealed that grinding induced solid-state interactions among 
the components of the ternary ground mixture were essential and had a great impact on 
nanoparticle formation.  Further investigations to find out how the nanoparticles are 
formed in the suspension would be an attractive research to get a better insight into the 
mechanism of nanoparticle formation and development of profitable applications for most 
of hydrophobic drugs.  To investigate the mechanism of drug nanoparticle formation, the 
probucol/PVP K17/SDS 1:3:1 ternary GM was used as a model system. 
 
1. Environmental SEM (ESEM) analysis 
 Environmental scanning electron microcopy has been developed recently and 
successfully utilized to study wet specimens.  Unlike conventional high vacuum SEM, 
ESEM allows for the retaining of pressure inside of the sample chamber during the 
imaging process.  Water pressure and temperature inside the sample chamber can be 
varied and correlated with the relative humidity of real atmospheric conditions 116-117).  The 
nanoparticles obtained from the probucol/PVP K17/SDS 1:3:1 GM were observed using 
ESEM (Fig. 3-1).  In agreement with the results of the light-scattering measurement, 
ESEM micrographs revealed the existence of sphere nanoparticles with size of around 100 
nm.  Due to the lack of a conductive coating during the operation of ESEM and the 
movement of the nanoparticles in the liquid state, the contrast of the images is low. 
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Fig. 3-1  Environmental SEM micrographs of probucol nanoparticles prepared from 
ternary ground mixture of probucol/PVP K17/SDS (1:3:1): 
(A) Probucol/PVP K17/SDS (11,500 X), (B) Magnification of (A) (60,000 X) 
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2. Nanoparticle formation obtained from binary ground mixtures 
 The results in chapter one indicated that the combined use of both PVP K17 and 
SDS played an important role for drug nanoparticle formation, while the drug-additive 
binary system had a limiting effectiveness for micronization when distilled water was used 
as the dispersing medium.  Co-existence of PVP and SDS was necessary for effective size 
reduction.  The nanoparticle formation of the binary GM of probucol/PVP K17 1:3 and 
probucol/SDS 1:1 dispersed into SDS and PVP solutions respectively, was investigated 
(Table 3-1).  It is clear from this table that all systems of the binary GMs showed no 
nanoparticle formation after dispersing into PVP or SDS solutions, indicating that both 
PVP and SDS were the required components during co-grinding process.  These results 
suggested that mechanochemical stress during grinding particularly induced simultaneous 
interactions of probucol-PVP and PVP-SDS to generate nanometer-sized particles of 
probucol.  Solid-state interactions were expected to contribute to the adsorption of PVP 
and SDS onto the drug nanoparticle surface in the suspension.    
 
3. Proposed mechanism for nanoparticle formation 
 The long-term stability of the suspension obtained from the ternary GM showed 
the effectiveness of PVP and SDS on the stabilization of suspended nanoparticles.  Figure 
3-2 demonstrates that probucol nanoparticles obtained from probucol/PVP K17/SDS 
ternary GM was still less than 150 nm even after storage for 28 days, indicating that the 
drug nanoparticle stably existed in the suspension.  It was suggested that grinding induced 
solid-state interactions among ternary components lead to the adsorption of the PVP-SDS 
complex at the particle surface as a result of the inhibitory effect of agglomerations. 
 Complexation of PVP and SDS both through electrostatic and hydrophobic 
interaction in aqueous solutions is recognized by many studies 63-76, 118).  Electrostatic 
interaction should exist between the negatively charged head group of SDS and the 
nitrogen atom on the pyrrolidone ring of PVP 66).  Figure 3-3 illustrates the complex 
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Table 3-1  Mean particle size of probucol particles obtained from the binary GM* in 
distilled water, PVP K17 and SDS solutions measured by FRA (0.1-700 µm) 
  
 Mean particle size (µm) 
Probucol intact in distilled water 
21.9 
Probucol/PVP K17 1:3 GM in distilled water 
23.3 
Probucol/PVP K17 1:3 GM in SDS solution 
30.0 
Probucol/SDS 1:1 GM in distilled water 
23.2 
Probucol/SDS 1:1 GM in PVP K17 solution 
27.9 
Probucol/PVP K17/SDS 1:3:1 GM in distilled water 
0.090** 
* Grinding time 30 min 
** Suspension obtained from the ternary GM and measured by UPA (0.003-6 µm).
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Fig. 3-2  Long-term stability of nanoparticles in suspension obtained from probucol/PVP 
K17/SDS ternary GM 
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Critical Aggregation Concentration (CAC) for SDS in PVP solution ≈ 0.08 mg/ml 
Critical Micelle Concentration (CMC) for SDS solution ≈ 2.30 mg/ml 
 
PVP                             SDS
CAC < [SDS] < CMC
PVP-SDS necklace structure
[SDS]=0.5 mg/ml
[SDS] = CAC
Starting point of association
between surfactant micelle
and polymer
[SDS] < CAC
Free SDS
(A) (B)
(C)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3-3  Schematic illustration of the complex formation of PVP and SDS in bulk solution 
and at the liquid/air surface 118).
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formation of PVP and SDS in an aqueous solution, as reported by Folmer and Kronberg 
118).  In the polymer/surfactant system, the critical aggregation concentration (CAC) has 
been used to describe interactions between the polymer and surfactant molecules.  The 
CAC indicated the onset of the binding or association between the surfactant micelles and 
the polymer.  At very low surfactant concentration, the surfactant molecules were only 
present as a monomer or single surfactant molecule (Fig. 3-3 (A)).  When the surfactant 
concentration reached the CAC, the surfactants started to form micelles together with the 
polymer in solution (Fig. 3-3 (B)).  This process occurred from SDS concentrations of 
0.08 mg/ml in the PVP solution, which was significantly lower than the CMC of the SDS 
bare molecule (0.20 mg/ml) 67).  The CAC was independent from the concentration of the 
polymer 67).  The concentration of SDS used in this study was 0.5 mg/ml, indicating the 
formation of the PVP-SDS complex as a “necklace structure” 70, 119) in the suspension 
obtained from the ternary GM (Fig. 3-3 (C)). 
 A possible mechanism of drug nanoparticle formation is illustrated in Fig. 3-4.  
The 13C NMR studies in chapter two revealed that grinding induced solid-state 
interactions of probucol-PVP and PVP-SDS contributed to the effective size reduction and 
production of the drug nanocrystals.  The interactions of drug-PVP and PVP-SDS 
appeared to enhance the adsorption of PVP and SDS onto drug nanoparticles after 
dispersing into water.  The SEM micrographs confirmed the presence of a few tens of 
nanometer-sized drug nanocrystals as primary nanoparticles in the ternary GM.  After the 
GM was dispersed into aqueous media, nano-crystalline drug particles were formed and 
their agglomeration immediately occurred to some extent, causing a sudden increase in 
size of up to 100-200 nm.  The agglomeration was effectively inhibited due to the 
adsorption of PVP and SDS on the particle surface.  Consequently, the particle size of 
drugs in the suspension remained constant for long time due to the inhibitory effect of 
adsorption by both PVP and SDS. 
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Fig. 3-4  Hypothetical model of the formation of nano-crystalline drug particles from the 
ternary GM 
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CHAPTER IV 
Drug nanoparticle formation from  
drug/HPMC/SDS ternary ground mixtures 
 
 The drug/PVP/SDS ternary grinding system has shown that it can be applicable 
for many kinds of hydrophobic drugs except flurbiprofen and tolbutamide.  To apply the 
grinding-induced nanomization procedure to flurbiprofen, tolbutamide and other 
hydrophobic drugs, different combinations of the components of the 
drug/polymer/surfactant system are investigated instead of the drug/PVP/SDS ternary 
system.  Drug nanoparticle formation is also expected by the ternary grinding if the 
molecular interactions among the components favorably take place.  
 At first, grinding-induced drug nanoparticle formation by the drug/hydroxy- 
propylmethylcellulose (HPMC)/SDS ternary system was investigated.  Flurbiprofen, 
which did not show nanoparticle formation by co-grinding with PVP and SDS, was used 
as the model drug to prepare the nanoparticles by co-grinding.   Effect of ternary 
components on the drug nanoparticle formation was also investigated using cellulose 
derivatives such as methylcellulose (MC) and hydroxypropylcellulose (HPC), and a bile 
salt which is sodium deoxycholate (NaDC).  The chemical structures and pharmaceutical 
properties of pharmaceutical excipients used in this study are shown in Fig. 4-1 
 
1. Physicochemical properties of the flurbiprofen/HPMC/SDS ternary ground 
mixture 
 Physicochemical properties of the flurbiprofen/HPMC/SDS ternary GM at a 
weight ratio of 1:3:1 were investigated by PXRD measurement and IR spectroscopy.   Fig. 
4-2 shows PXRD patterns of flurbiprofen/HPMC/SDS ternary PM and GM.  The PM 
showed characteristic X-ray diffraction peaks of both flurbiprofen crystals and SDS 
crystals (Fig. 4-2 (C)).  The ternary GM exhibited crystalline SDS peaks, while the X-ray 
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Sodium deoxycholate (NaDC)
Anionic surfactant
Molecular weight: 414.56
Melting point: 301-303 °C (with decomposition)
Critical micelle concentration (CMC) at 25ºC: 6.5 mM (2.7 mg/ml) 120)
R = H, CH3 ----------------------------Methylcellulose (MC)
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Fig. 4-1  Chemical structures and physicochemical properties of the pharmaceutical 
excipients used in this study 
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Fig. 4-2  PXRD patterns of flurbiprofen/HPMC/SDS systems: 
(A) Flurbiprofen intact, (B) HPMC/SDS GM (weight ratio 3:1), (C) 
Flurbiprofen/HPMC/SDS PM (weight ratio 1:3:1), (D) Flurbiprofen/HPMC/SDS GM 
(weight ratio 1:3:1), (E) Flurbiprofen/HPMC/SDS GM after storage at 40ºC, RH 22% for 
2 months  
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diffraction peaks of flurbiprofen were hardly observed because of a decrease of the 
crystallinity by the mechanical stress during grinding.  Since the small particles 
surrounded by the additives did not clearly show the diffraction peaks in the X-ray 
diffractogram, the solid state of flurbiprofen in the GM might be the amorphous and/or 
fine crystallites.    
 The molecular interaction between flurbiprofen and HPMC or SDS was 
investigated by FT-IR spectroscopy (Fig. 4-3).  In flurbiprofen/SDS binary GM, C=O 
stretching band of flurbiprofen was observed at 1701cm-1, which was the same position to 
the intact crystals.  In the case of flurbiprofen/HPMC binary GM, however, the position of 
C=O stretching band completely shifted to higher wave number, 1734cm-1, indicating that 
flurbiprofen interacted with HPMC through hydrogen bonding.  From the comparison of 
the IR spectra of ternary PM and GM, the peak shift of C=O stretching band was observed 
as a small shoulder at 1728 cm-1 after grinding.  As flurbiprofen did not interact with SDS 
(Fig. 4-3 (C)), the small shoulder would be attributed to the interaction between 
flurbiprofen and HPMC molecules.    
 
2. Flurbiprofen nanoparticle formation and stability study  
 Figure 4-4 shows particle size distribution patterns of flurbiprofen/HPMC/ SDS 
GM dispersion into distilled water.  The determined volumetric particle size of 
flurbiprofen nanoparticles was 346 nm.  After storage for 4 h, the distribution pattern did 
not change, showing the high stability of the nanoparticles formed.  The effect of HPMC 
and SDS on flurbiprofen nanoparticle formation was investigated in order to estimate the 
mechanism of the drug nanoparticle formation (Table 4-1).  The mean particle size of 
flurbiprofen crystals was 12.5 µm.  Flurbiprofen/HPMC binary GM showed no particle 
size reduction, some molecular interaction between flurbiprofen and HPMC was even 
observed in IR spectra (Fig. 4-3).  On the contrary, flurbiprofen/SDS binary GM 
effectively exhibited the reduction of the drug particle size to ca. 1.5 µm. 
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Fig. 4-3  IR spectra of flurbiprofen/HPMC/SDS systems: 
(A) Flurbiprofen intact, (B) HPMC/SDS GM (weight ratio 3:1), (C) Flurbiprofen/SDS 
GM (weight ratio 1:1), (D) Flurbiprofen/HPMC GM (weight ratio 1:3), (E) 
Flurbiprofen/HPMC/SDS PM (weight ratio 1:3:1), (F) Flurbiprofen/HPMC/SDS GM 
(weight ratio 1:3:1) 
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Fig. 4-4  Photographs of the suspensions obtained from flurbiprofen/HPMC/SDS 1:3:1 
PM and GM  
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Table 4-1  Mean particle size of drug in the suspensions obtained from PM, binary and 
ternary GMs of flurbiprofen/HPMC/SDS systems measured by FRA (0.1-700 µm). 
 
Composition (weight ratio) Mean particle size (µm) 
Flurbiprofen intact crystal 12.5 
Flurbiprofen/HPMC/SDS 1:3:1, PM 15.1 
Flurbiprofen/HPMC 1:3, GM 16.7 
Flurbiprofen/SDS 1:1, GM 1.49 
Flurbiprofen/HPMC/SDS 1:3:1, GM* 0.346 
*Suspension obtained from ternary GM was measured by UPA (0.003-6 µm). 
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 These results indicated that the combined use of HPMC and SDS played an 
important role for the flurbiprofen nanoparticle formation, even drug-SDS binary system 
showed some effectiveness for the particle size reduction.  Effect of storage condition of 
GM on the powder properties was investigated.  Powder X-ray diffraction pattern of the 
GM did not changed after storage at 40ºC and RH 22% for 2 months (Fig. 4-2 (E)) and 
particle size of the GM after dispersing into water was 370 nm, which was almost same as 
that before the storage (Fig. 4-5).  Mean particle size of the dispersed GM was still less 
than 350 nm after storage of the GM suspension at 25°C for 1 month as shown in Fig. 4-6.  
These results indicated that both flurbiprofen /HPMC/SDS ternary GM and flurbiprofen 
nanoparticles prepared by dispersing the GM into aqueous media were both stable under 
conventional storage conditions.    
 
3. Application of the drug/HPMC/SDS ternary grinding method for other 
hydrophobic drugs 
 Drug nanoparticle formation by drug/HPMC/SDS ternary grinding method was 
further investigated by using other hydrophobic drugs to evaluate wide applicability of 
this method.  Table 4-2 shows the mean particle size observed after dispersing 
drug/HPMC/SDS ternary GM into water.  Tolbutamide demonstrated stable nanoparticle 
formation compared with that of the drug/PVP/SDS system, where probucol, phenytoin 
and griseofulvin also showed drug nanoparticle formation by co-grinding with HPMC and 
SDS.    
 Molecular interaction between HPMC and SDS developed during by the co-
ground process with drug crystals seemed to play a key role for the effective size 
reduction.  Alli et al. reported that ion-dipole interaction of SDS with the ethereal oxygen 
in HPMC contributed to the molecular interaction between HPMC and SDS not only in 
the aqueous solution but also in the solid state 121).  Hydrophobic interaction between SDS 
molecules also produced in the process of HPMC/SDS aggregate formation in the aqueous 
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Fig. 4-5  Changes in particle size distribution pattern of the of flurbiprofen/HPMC/SDS 
GM dispersed into distilled water 
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Fig. 4-6  Long-term stability of suspension obtained from flurbiprofen/HPMC/SDS GM 
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solution.  As HPMC has an intrinsic surface activity, the combined use of both HPMC and 
SDS may result in an effective size reduction of flurbiprofen crystals.  Molecular 
interaction between flurbiprofen and HPMC would be another key interaction that 
influences the effective size reduction as shown in Fig. 4-3.  In drug/PVP/SDS ternary 
GMs, molecular interaction between PVP and SDS, which has been reported by Li et al. 
66), also played an important role in drug nanoparticle formation.  However, a molecular 
interaction between flurbiprofen and PVP was not observed by IR spectroscopy in 
flurbiprofen/PVP/SDS ternary GMs.  That would be the reason why flurbiprofen/PVP/ 
SDS ternary GM did not show effective size reduction of the drug.  As co-existence of 
HMPC and SDS during the grinding process with flurbiprofen crystals was required for 
the effective particle size reduction and the binary system showed no nanoparticle 
formation, molecular interaction not only between flurbiprofen and HPMC but also 
between HPMC and SDS was supposed to be important for the nanoparticle formation. 
 
4. Effect of ternary composition on drug nanoparticle formation 
 The effect of ternary components on the drug nanoparticle formation was 
investigated by using cellulose derivatives such as methylcellulose (MC) and 
hydroxypropylcellulose (HPC) instead of HPMC (Table 4-3).  Effective size reduction to 
a submicron level was also observed with MC and HPC.  The most effective size 
reduction was observed for flurbiprofen or tolbutamide/HPC/SDS system.  These results 
indicated that cellulose derivatives were promising candidates for the grinding-induced 
drug nanoparticle formation instead of PVP.    
 The effect of polymer hydrophobicity of the cellulose derivatives on the 
interaction with SDS has been investigated previously by titration microcalorimetry and 
the overall mechanism of interaction was found to be similar for all the cellulose 
derivatives 122).  The polymer-SDS interaction was dominated by polymer-surfactant and 
surfactant-surfactant interactions, which depended on the SDS concentrations.  In 
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Table 4-3  Effect of cellulose derivatives on mean particle size of the micronized drug 
particles obtained from ternary GM* after dispersion into distilled water 
 
Mean particle size (nm) 
Flurbiprofen  Tolbutamide  
t = 0 t = 4h  t = 0 t = 4h 
HPMC/SDS 346 354  298 399 
HPC/SDS 298 310  251 301 
MC/SDS 441 467  613 685 
* Drug:polymer:surfactant, 1:3:1 w/w/w, ground for 30 min 
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drug/polymer/SDS ternary GMs, the molecular interaction between cellulose derivative 
and SDS would not be different from cellulose derivatives used, even that between 
cellulose derivative and drug should be different. 
 To apply the ternary grinding method with the other surfactant, a natural bile salt 
such as sodium deoxycholate (NaDC) was also used as anionic surfactant instead of SDS.    
The effect of the surfactant component on nanoparticle formation was investigated by 
grinding a hydrophobic drug with PVP, HPMC or MC with NaDC.  Four hydrophobic 
drugs (flurbiprofen, tolbutamide, probucol and phenytoin) were used in this study.  Table 
4-4 shows the mean particle size observed after dispersion of the drug/polymer/NaDC 
ternary GM into water.  All GMs, except tolbutamide/PVP/NaDC, produced a suspension 
with mean particle size at submicron level even after storage for 4 h.  These results 
indicated that a natural bile salt was also an alternative surface active agent to SDS for 
grinding-induced drug nanoparticle formation.   
 Table 4-4 indicated that tolbutamide did not show nanoparticle formation by co-
grinding with PVP and NaDC.  In addition, the particle size of flurbiprofen/PVP/NaDC 
after storage of the suspension for 4 h was relatively large.  The suspensions of 
flurbiprofen or tolbutamide/PVP/NaDC GM displayed less effective size reduction 
comparatively with those of probucol or phenytoin/PVP/NaDC GM.  The results in 
chapter I also demonstrated that flurbiprofen and tolbutamide did not form nanoparticles 
by co-grinding with PVP and SDS.  In chapter II, FT-IR spectroscopy (Fig. 4-3) shows 
that the molecular interaction between drug and polymer appeared to play a key role for 
nanoparticle formation.  These results suggested that a specific type of polymer for the 
drug was required for the effective particle size reduction.  Cellulose derivatives were 
expected to be promising candidates for tolbutamide and flurbiprofen for the grinding-
induced drug nanoparticle formation instead of PVP.   
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 As shown in this chapter, the ternary co-grinding of the drug with polymer, and 
surfactant with various combinations was applicable for most of the poorly water-soluble 
drugs.  In conclusion, the drug/water-soluble polymer/surfactant ternary grinding could be 
a promising method to prepare drug nanoparticles for the purpose of bioavailability 
enhancement of poorly water-soluble drugs. 
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CONCLUSIONS 
  
Conclusions for chapter I 
1. Nanoparticles of drug crystals, easily obtained by using a ternary ground mixture 
of drug, PVP K17 and SDS at a weight ratio of 1:3:1, could only be hardly 
produced from a binary ground mixture of the drug with PVP K17 or SDS.   
2. The nanosuspension prepared from the GM was stable for 1 month, as the particle 
agglomeration was effectively inhibited by the adsorption of both PVP and SDS on 
the surface of crystalline particles.   
3. The drug/PVP/SDS ternary grinding method was successfully applied for the 
preparation of nanoparticles of hydrophobic drugs.  
 
Conclusions for chapters II & III 
1. The 13C NMR studies revealed that solid-state interactions of both probucol/PVP 
and PVP/SDS on grinding played a key role for probucol nanoparticle formation.  
2. In ternary GM, simultaneous grinding-induced interactions of probucol-PVP and 
PVP-SDS were accelerated with the decrease of the PVP molecular weight, 
leading to size reduction of probucol with lower PVP molecular weight. 
3. Binary ground mixtures of probucol and PVP indicated an interaction with PVP 
regardless of the PVP molecular weight, whereas the interaction in the binary 
mixtures of PVP and SDS was significantly affected by the molecular weight of 
PVP.   
4. The nanoparticles in the ternary GM existed as primary particles of the drug 
nanocrystal.  Specific interactions among the components in the ternary ground 
mixture developed during grinding produced stable nanoparticles in suspension.  
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Conclusions for chapter IV 
1. Since the flurbiprofen/ HPMC /SDS ternary GM and the drug suspension showed 
good stability, HPMC is a promising hydrophilic polymer for flurbiprofen 
nanoparticle formation.    
2. It was suggested that molecular interactions both between HPMC and SDS, and 
between flurbiprofen and HPMC were important for particle size reduction.    
3. The drug/HPMC/SDS ternary grinding method was applicable not only to 
flurbiprofen but also to other hydrophobic drugs.    
4. Drug nanoparticles were also obtained with other cellulose derivatives and bile 
salts, indicating that these were alternative pharmaceutical excipients to PVP and 
SDS for the grinding-induced drug nanoparticle formation. 
 
Conclusions 
1. The drug/PVP/SDS ternary grinding method was successfully applied for the 
preparation of nanoparticles of hydrophobic drugs.   
2. Co-existence of both PVP and SDS during the grinding process with drug 
crystals was required for effective particle size reduction since the binary systems 
of drug/PVP and drug/SDS showed no nanoparticle formation. 
3. Nanoparticle formation and stabilization were attributable to grinding-induced 
solid-state interactions among components of the drug/PVP/SDS ternary system. 
4. Drug/water-soluble polymer/surfactant ternary grinding could be a promising 
method to prepare the drug nanoparticles for the purpose of bioavailability 
enhancement of poorly water-soluble drugs. 
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